143 related articles for article (PubMed ID: 10023509)
1. Behavioral, neuroendocrine, and cardiovascular response to flumazenil: no evidence for an altered benzodiazepine receptor sensitivity in panic disorder.
Ströhle A; Kellner M; Holsboer F; Wiedemann K
Biol Psychiatry; 1999 Feb; 45(3):321-6. PubMed ID: 10023509
[TBL] [Abstract][Full Text] [Related]
2. Effect of flumazenil in lactate-sensitive patients with panic disorder.
Ströhle A; Kellner M; Yassouridis A; Holsboer F; Wiedemann K
Am J Psychiatry; 1998 May; 155(5):610-2. PubMed ID: 9585710
[TBL] [Abstract][Full Text] [Related]
3. Flumazenil provocation of panic attacks. Evidence for altered benzodiazepine receptor sensitivity in panic disorder.
Nutt DJ; Glue P; Lawson C; Wilson S
Arch Gen Psychiatry; 1990 Oct; 47(10):917-25. PubMed ID: 2171449
[TBL] [Abstract][Full Text] [Related]
4. Behavioral, biochemical, and cardiovascular responses to the benzodiazepine receptor antagonist flumazenil in panic disorder.
Woods SW; Charney DS; Silver JM; Krystal JH; Heninger GR
Psychiatry Res; 1991 Feb; 36(2):115-27. PubMed ID: 1850142
[TBL] [Abstract][Full Text] [Related]
5. Behavioral, neuroendocrine, and cardiovascular response to flumazenil: no evidence for an altered benzodiazepine receptor sensitivity in panic disorder.
Potokar J; Lawson C; Wilson S; Nutt D
Biol Psychiatry; 1999 Dec; 46(12):1709-11. PubMed ID: 10624555
[No Abstract] [Full Text] [Related]
6. Effects of the benzodiazepine antagonist flumazenil in PTSD.
Randall PK; Bremner JD; Krystal JH; Nagy LM; Heninger GR; Nicolaou AL; Charney DS
Biol Psychiatry; 1995 Sep; 38(5):319-24. PubMed ID: 7495926
[TBL] [Abstract][Full Text] [Related]
7. Rapid tryptophan depletion following cognitive behavioural therapy for panic disorder.
Bell C; Hood S; Potokar J; Nash J; Adrover M; Frampton C; Hince D; Rich A; Argyropoulos S; Nutt D
Psychopharmacology (Berl); 2011 Feb; 213(2-3):593-602. PubMed ID: 19823804
[TBL] [Abstract][Full Text] [Related]
8. Stressful reactions and panic attacks induced by flumazenil in chronic benzodiazepine users.
Bernik MA; Gorenstein C; Vieira Filho AH
J Psychopharmacol; 1998; 12(2):146-50. PubMed ID: 9694026
[TBL] [Abstract][Full Text] [Related]
9. Flumazenil challenge in social phobia.
Coupland NJ; Bell C; Potokar JP; Dorkins E; Nutt DJ
Depress Anxiety; 2000; 11(1):27-30. PubMed ID: 10723632
[TBL] [Abstract][Full Text] [Related]
10. Response to flumazenil in the late luteal phase and follicular phase of the menstrual cycle in healthy control females.
Bell EC; Baker GB; Poag C; Bellavance F; Khudabux J; Le Mellédo JM
Psychopharmacology (Berl); 2004 Mar; 172(3):248-54. PubMed ID: 14712334
[TBL] [Abstract][Full Text] [Related]
11. Acute effects of low-dose flumazenil in panic disorder.
Maddock RJ
J Clin Psychopharmacol; 1998 Jun; 18(3):258-61. PubMed ID: 9617991
[No Abstract] [Full Text] [Related]
12. Response to flumazenil in women with premenstrual dysphoric disorder.
Le Mellédo JM; Van Driel M; Coupland NJ; Lott P; Jhangri GS
Am J Psychiatry; 2000 May; 157(5):821-3. PubMed ID: 10784479
[TBL] [Abstract][Full Text] [Related]
13. Effects of flumazenil on cholecystokinin-tetrapeptide-induced panic symptoms in healthy volunteers.
Bradwejn J; Koszycki D; Couëtoux du Tertre A; Paradis M; Bourin M
Psychopharmacology (Berl); 1994 Mar; 114(2):257-61. PubMed ID: 7838917
[TBL] [Abstract][Full Text] [Related]
14. Enhanced selective attention after low-dose administration of the benzodiazepine antagonist flumazenil.
Smolnik R; Pietrowsky R; Fehm HL; Born J
J Clin Psychopharmacol; 1998 Jun; 18(3):241-7. PubMed ID: 9617984
[TBL] [Abstract][Full Text] [Related]
15. Flumazenil attenuates the pituitary response to CRH in healthy males.
Ströhle A; Wiedemann K
Eur Neuropsychopharmacol; 1996 Nov; 6(4):323-5. PubMed ID: 8985717
[TBL] [Abstract][Full Text] [Related]
16. GABA-benzodiazepine receptor function in alcohol dependence: a combined 11C-flumazenil PET and pharmacodynamic study.
Lingford-Hughes AR; Wilson SJ; Cunningham VJ; Feeney A; Stevenson B; Brooks DJ; Nutt DJ
Psychopharmacology (Berl); 2005 Aug; 180(4):595-606. PubMed ID: 15864554
[TBL] [Abstract][Full Text] [Related]
17. SPECT [I-123]iomazenil measurement of the benzodiazepine receptor in panic disorder.
Bremner JD; Innis RB; White T; Fujita M; Silbersweig D; Goddard AW; Staib L; Stern E; Cappiello A; Woods S; Baldwin R; Charney DS
Biol Psychiatry; 2000 Jan; 47(2):96-106. PubMed ID: 10664825
[TBL] [Abstract][Full Text] [Related]
18. Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study.
Malizia AL; Cunningham VJ; Bell CJ; Liddle PF; Jones T; Nutt DJ
Arch Gen Psychiatry; 1998 Aug; 55(8):715-20. PubMed ID: 9707382
[TBL] [Abstract][Full Text] [Related]
19. A pilot controlled study of the effects of flumazenil in posttraumatic stress disorder.
Coupland NJ; Lillywhite A; Bell CE; Potokar JP; Nutt DJ
Biol Psychiatry; 1997 May; 41(9):988-90. PubMed ID: 9110106
[No Abstract] [Full Text] [Related]
20. Lack of specific association between panicogenic properties of caffeine and HPA-axis activation. A placebo-controlled study of caffeine challenge in patients with panic disorder.
Masdrakis VG; Markianos M; Oulis P
Psychiatry Res; 2015 Sep; 229(1-2):75-81. PubMed ID: 26243374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
